Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma

JAMA - Journal of the American Medical Association

Volumn 313, Issue 24, 2015, Pages 2449-2455

  Loeb, Stacy ^a   Folkvaljon, Yasin ^b   Lambe, Mats ^b,c   Robinson, David ^d   Garmo, Hans ^e   Ingvar, Christian ^f   Stattin, Pär ^d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGE; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER RISK; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; EDUCATIONAL STATUS; ERECTILE DYSFUNCTION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MELANOMA; PRESCRIPTION; PRIORITY JOURNAL; SWEDEN; VERY ELDERLY; ANIMAL; CASE CONTROL STUDY; CHEMICALLY INDUCED; MIDDLE AGED; REGISTER; RISK FACTOR; SKIN TUMOR; SOCIOECONOMICS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, BASAL CELL; CASE-CONTROL STUDIES; DRUG PRESCRIPTIONS; ERECTILE DYSFUNCTION; HUMANS; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; REGISTRIES; RISK FACTORS; SKIN NEOPLASMS; SOCIOECONOMIC FACTORS; SWEDEN;

EID: 84937605684     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.6604     Document Type: Article

References (20)

1. Arozarena I, Sanchez-Laorden B, Packer L, et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell. 2011;19(1):45-57.
2. Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med. 2014;174(6):964-970.
3. Grichnik JM. Sildenafil may elevate melanoma risk. Dermatol Ther. 2014;27(5):313.
4. Robinson JK. Role of sildenafil in melanoma incidence and mortality. JAMA Intern Med. 2014;174(6):970-971.
5. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50-56.
6. Frederick LR, Cakir OO, Arora H, Helfand BT, McVary KT. Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients. J Sex Med. 2014;11(10):2546-2553.
7. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58: 295-300.
8. Van Hemelrijck M, Wigertz A, Sandin F, et al NPCR and PCBaSe Sweden. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data base Sweden 2.0. Int J Epidemiol. 2013;42(4):956-967.
9. Eriksson H, Lyth J, Månsson-Brahme E, et al. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. J Clin Oncol. 2014;32(13):1356-1364.
10. Socialstyrelsen. National Board of Health and Welfare: the prescribed drug register [in Swedish]. http://www.nepi.net/Socialstyrelsens-laekemedelsregister.htm. Accessed May 28, 2015.
11. Doggrell S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int J Impot Res. 2007;19(3):281-295.
12. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185(3):833-839.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
14. Socialstyrelsen. Statistikdatabas för cancer [in Swedish]. http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer. Accessed May 21, 2015.
15. Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol. 2011;65(5)(suppl 1):S78-S86.
16. Plym A, Folkvaljon Y, Garmo H, et al. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer. J Sex Med. 2014;11(8):2100-2108.
17. Nordin M, Dackehag M, Gerdtham UG. Socioeconomic inequalities in drug utilization for Sweden: evidence from linked survey and register data. Soc Sci Med. 2013;77:106-117.
18. Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. Br J Dermatol. 2015;172(4):885-915.
19. Li WQ, Qureshi AA, Ma J, et al. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol. 2013;31(35):4394-4399.
20. Shaeer O. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers. J Sex Med. 2013;10(2):532-540.